BerGenBio ASA (LTS:0RU5) Days Payable : 0.00 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is BerGenBio ASA Days Payable?

BerGenBio ASA's average Accounts Payable for the three months ended in Sep. 2024 was kr8.17 Mil. BerGenBio ASA's Cost of Goods Sold for the three months ended in Sep. 2024 was kr0.00 Mil.

The historical rank and industry rank for BerGenBio ASA's Days Payable or its related term are showing as below:

LTS:0RU5's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.37
* Ranked among companies with meaningful Days Payable only.

BerGenBio ASA's Days Payable stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00). stayed the same

BerGenBio ASA Days Payable Historical Data

The historical data trend for BerGenBio ASA's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BerGenBio ASA Days Payable Chart

BerGenBio ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

BerGenBio ASA Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of BerGenBio ASA's Days Payable

For the Biotechnology subindustry, BerGenBio ASA's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BerGenBio ASA's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BerGenBio ASA's Days Payable distribution charts can be found below:

* The bar in red indicates where BerGenBio ASA's Days Payable falls into.

BerGenBio ASA Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

BerGenBio ASA's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (29.634	+	18.605)	/	2 )	/	0	*	365
=	24.1195					/	0	*	365
=	N/A

BerGenBio ASA's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (8.624	+	7.71)	/	2 )	/	0	*	365 / 4
=	8.167					/	0	*	365 / 4
=	N/A

BerGenBio ASA Days Payable Related Terms

Thank you for viewing the detailed overview of BerGenBio ASA's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

BerGenBio ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BerGenBio ASA (LTS:0RU5) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

BGBIO:Norway 7BG0:Germany

Address

Mollendalsbakken 9, Bergen, NOR, 5009

Website

https://www.bergenbio.com

BerGenBio ASA is a clinical-stage biopharmaceutical Company focused on developing novel medicines for aggressive diseases. The company's clinical asset, bemcentinib, targeting the receptor tyrosine kinase AXL, is currently in development in a Ph1b/2a study in 1L STK 11 mutated NSCLC and preclinical development for severe respiratory infections.

BerGenBio ASA Headlines

No Headlines